Notice of Allowability	Application No.	Applicant(s)	
	10/759,860	WANG ET AL.	
	Examiner	Art Unit	
	Elizabeth C. Kemmerer, Ph.D.	1646	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to *the amendment of 10 May 2007*.

2. ☒ The allowed claim(s) is/are *1, 18, 19, 22-38*.

3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
   a) ☐ All b) ☐ Some* c) ☐ None of the:
      1. ☐ Certified copies of the priority documents have been received.
      2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
      3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
      1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
   (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application
6. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____ .
7. ☐ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

Elizabeth C. Kemmerer

ELIZABETH C. KEMMERER. PH.D.
PRIMARY EXAMINER

Amendment to the Claims. Please amend claims 1, 18 and 19, cancel claims 15 and 16, without prejudice, and add new claims 32-38 as follows.

Listing of the Claims. This listing replaces any previous listing.

1 (Currently amended). A method for treating an inflammatory response in the ~~gastrointestinal tract~~ small intestine, of a subject ~~by modulating physiology or development of a macrophage cell expressing a receptor for a TECK polypeptide, which polypeptide comprises the amino acid sequence set forth in Gln1 to Leu127 of SEQ ID NO: 4~~, comprising administering ~~contacting the cell with~~ an antagonist antibody or an antigen-binding fragment thereof that binds specifically to an epitope in a polypeptide which epitope consists of amino acids Gln1 to Leu127 of SEQ ID NO: 4, to said subject ~~the polypeptide~~.

2-17 (Cancelled).

18 (Currently amended). The method of Claim 1 wherein the ~~gastrointestinal inflammation~~ inflammatory response is Crohn's disease.

19 (Currently amended). The method of Claim 1 wherein the ~~gastrointestinal inflammation~~ inflammatory response is inflammatory bowel disease.

20-21 (Cancelled).

22 (Previously presented). The method of Claim 1 wherein the antibody or antigen-binding fragment is conjugated to a chemical moiety.

23 (Currently amended). The method of Claim 1 wherein ~~the antigen-binding~~ said antibody or fragment is a fragment and the fragment is a Fv fragment.

24 (Currently amended). The method of Claim 1 wherein said antibody or fragment is a ~~the antigen-binding~~ fragment and the fragment is a Fab fragment.

25 (Currently amended). The method of Claim 1 wherein said antibody or fragment is a ~~the antigen-binding~~ fragment and the fragment is a Fab2 fragment.

26 (Currently amended). The method of Claim 1 wherein said antibody or fragment is an antibody and the antibody is a monoclonal antibody.

27 (Currently amended). The method of Claim 1 wherein said antibody or fragment is an antibody and the antibody is a polyclonal antibody.

28 (Previously presented). The method of Claim 1 wherein the antibody or antigen-binding fragment exhibits a Kd greater than 300 μM to the TECK polypeptide.

29 (Previously presented). The method of Claim 1 wherein the antibody or antigen-binding fragment exhibits a Kd greater than 30 μM to the TECK polypeptide.

30 (Previously presented). The method of Claim 1 wherein the antibody or antigen-binding fragment exhibits a Kd greater than 10 μM to the TECK polypeptide.

31 (Previously presented). The method of Claim 1 wherein the antibody or antigen-binding fragment exhibits a Kd greater than 3 μM to the TECK polypeptide.

32 (New). The method of claim 1 wherein the antibody or fragment is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

33 (New). A method for treating Crohn's disease small intestine inflammation, comprising administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antagonist monoclonal antibody that binds specifically to an epitope in a polypeptide which epitope consists of amino acids Gln1 to Leu127 of SEQ ID NO: 4, to said subject.

34 (New). A method for treating inflammatory bowel disease small intestine inflammation, comprising administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antagonist monoclonal antibody that binds specifically to an epitope in a polypeptide which epitope consists of amino acids Gln1 to Leu127 of SEQ ID NO: 4, to said subject.

35 (New). The method of Claim 1 wherein the antibody or fragment is an antibody and the antibody is an anti-idiotypic antibody.

36 (New). The method of Claim 1 wherein the antibody or fragment is recombinant.

37 (New). The method of Claim 1 wherein the antibody or fragment is an antibody and the antibody is a chimeric antibody.

38 (New). The method of Claim 1 wherein the antibody or fragment is an antibody and the antibody is a humanized antibody.